Biological Background

The Neuropeptide Y Receptor Type 2 (NPY2R), also known as the Y2 receptor, is a class A GPCR predominantly expressed in the central and peripheral nervous systems, regulating appetite, energy expenditure, and glucose homeostasis. NPY2R couples to inhibitory Gαi/o proteins, modulating appetite suppression and thermogenic pathways through distinct physiological mechanisms. Emerging NPY2R agonist and antagonist programs represent promising therapeutic strategies for obesity and metabolic disorders.

This bioassay kit supports pharmaceutical companies developing NPY2R-targeted therapies for obesity, metabolic syndrome, and energy balance disorders. Applications include agonist and antagonist characterization, potency testing, neutralizing antibody screening, and preclinical drug discovery for obesity therapeutics.

Eurofins DiscoverX's cAMP Hunter™ NPY2R kit provides ready-to-use CHO-K1 cells engineered for sensitive Gαi/o-coupled cAMP inhibition measurement, delivering reliable results for comprehensive NPY2R pharmacology profiling and obesity drug development.

Product Highlights
  • Gαi/o-coupled cAMP inhibition assay: Measures NPY2R activation through adenylyl cyclase inhibition and decreased cAMP production for comprehensive receptor characterization
  • Ready-to-use cryopreserved cells: CHO-K1 NPY2R cells provided in single-use format for rapid implementation from hit identification to lot release testing
  • Complete kit components: Includes cells, EFC-based cAMP detection reagents, cell plating media, dilution buffer, control agonist (NPY/Peptide YY), and 96-well assay plates
  • Obesity research validated: Optimized for studying NPY2R ligands relevant to obesity, metabolic syndrome, and energy homeostasis therapeutics, supporting both agonist and antagonist development

cAMP Hunter NPY2R Assay Principle

The cAMP Hunter™ NPY2R Bioassay Kit enables real-time monitoring of NPY2R receptor activity upon compound addition. CHO-K1 cells stably overexpressing human NPY2R are incubated with test compounds, and receptor activation is directly quantified using Enzyme Fragment Complementation (EFC) technology to measure intracellular cAMP modulation. The homogeneous, cell-based assay provides a sensitive and reproducible readout of both agonist potency and antagonist activity, making it ideal for rapid screening, lead optimization, and pharmacological characterization of NPY2R-targeted therapeutics.

cAMP Hunter NPY2R Bioassay Kit